In late July, the Food and Drug Administration (FDA) approved selective use of Praluent, the first of a new class of cholesterol-lowering drugs (PCSK9 inhibitors). A similar drug, Repatha, is expected to be approved this month. The reported results so...
Filed under: Public Health, Quality, Population Health, Featured, Costs and Spending, Drugs and Medical Technology, regulation, FDA, genetic conditions, cholesterol-lowering drugs, rapid learning, Praluent, Repatha